Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Perspective: Discussing the NASH landscape in the aftermath of the Akero's efruxifermin results

Ticker(s): AKRO, ENTB, MDGL, LLY, NVO

Who's the expert?

Institution: University of Oxford (UK) and Pinnacle Clinical Research (US)

Medical Director of Pinnacle Clinical Research.
Leading authority on liver diseases.
Peer-reviewer for over 20 medical journals and internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 150 peer reviewed publications in these fields.

Interview Goal

This conversation will focus on Akero's recent announcement of their Phase 2b SYMMETRY study results evaluating efruxifermin (EFX) in patients with compensated cirrhosis due to NASH.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.